Humacyte, Inc. (Nasdaq: HUMA), a biotechnology company focused on creating universally implantable bioengineered human tissues, recently announced two notable scientific publications highlighting the potential of its acellular tissue–engineered vessel (ATEV™) platform in both clinical and preclinical settings. Together, these updates underscore Humacyte’s progress in advancing biofabricated vascular grafts from trauma care into cardiovascular surgery.
Symvess in Hospital-Acquired Vascular Complications
In the Journal of Vascular Surgery, researchers reported outcomes from 12 patients with hospital-acquired vascular complications who were treated with Symvess™, Humacyte’s FDA-approved ATEV for urgent extremity arterial repair.
- Key findings included 92% secondary patency at an average follow-up of 23.3 months, 100% limb salvage, and no conduit infections.
- The patients required arterial repair following events such as peripheral artery interventions, tumor resections, and orthopedic surgeries.
Symvess is designed as an off-the-shelf vascular conduit, eliminating the need to harvest a patient’s own vein and avoiding the use of synthetic grafts. The U.S. Food and Drug Administration approved Symvess in December 2024 for use in adults who require urgent revascularization when autologous vein grafts are not feasible. These results suggest that Symvess may provide a practical, infection-resistant option for surgeons managing complex hospital-acquired vascular injuries.
Preclinical Data for Coronary Tissue-Engineered Vessel (CTEV)
Separately, in JACC: Basic to Translational Science, Humacyte published preclinical data evaluating its Coronary Tissue-Engineered Vessel (CTEV) as a conduit for coronary artery bypass grafting (CABG).
- In a study of five nonhuman primates, all implanted CTEVs remained patent through six months, recellularized with host coronary cells, and demonstrated adaptive remodeling that reduced the initial size mismatch with native coronary arteries.
CABG typically relies on the saphenous vein, which has a failure rate of roughly 50% at 10 years and is not always available in sufficient quality. The CTEV, a 3.5 mm small-diameter version of the ATEV, may provide an alternative conduit. Humacyte plans to submit an Investigational New Drug (IND) application to the FDA in late 2025 to begin a first-in-human study of CTEV, a step that could introduce a new class of grafts into coronary surgery.
About Humacyte and Its Platform
Founded to address the global shortage of durable, human-compatible grafts and tissues, Humacyte develops bioengineered, acellular human tissues at commercial scale. The company’s platform uses a proprietary biomanufacturing system to grow large-diameter vessels from human cells on polymer scaffolds, which are then decellularized to create universally implantable grafts. These ATEVs are designed to integrate with the patient’s own cells after implantation, allowing natural remodeling and minimizing immune rejection.
The Business of Biofabrication 
Leave a comment